Stockholm Calls: Docs Eye New Tactics for Type 2 Diabetes at EASD

New data on tirzepatide for weight loss and potential type 2 diabetes remission as well as an update on use of dapagliflozin for heart failure will be presented at the first in-person EASD meeting for 3 years.
Medscape Medical News

source https://www.medscape.com/viewarticle/980769?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?